Choline-PET boosts mpMRI for prostate cancer detection

The addition of F-18 choline PET to multiparametric MRI (mpMRI) can significantly...Read more on AuntMinnie.comRelated Reading: Prostate cancer patients prefer mpMRI over biopsy Ga-68 PSMA PET/MRI, mpMRI work for prostate cancer analysis mpMRI reduces unnecessary prostate biopsies Choline-PET with mpMRI is cost-effective for prostate cancer Prostate imaging director can improve MRI efficiency
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Contributors : Radoslaw Januchowski ; Dominika Kazmierczak ; Marcin RucinskiSeries Type : Non-coding RNA profiling by arrayOrganism : Homo sapiens ; synthetic constructAlthough many genes associated with the development of resistance to chemotherapy are known, the mechanisms of their regulation are still poorly understood. One of the ways to regulate gene expression is regulation at mRNA level by small noncoding RNA particles – designated as a micro RNA (miRNA). Changes in miRNA expression were also observed in cell line studyes. Downregulation of miR-31 expression correlated with taxane resistance in ovarian cancer ...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by array Homo sapiens synthetic construct Source Type: research
Publication date: Available online 6 April 2020Source: European UrologyAuthor(s): David P. Dearnaley, Daniel R. Saltzstein, John E. Sylvester, Lawrence Karsh, Bryan A. Mehlhaff, Christopher Pieczonka, James L. Bailen, Hongliang Shi, Zhan Ye, Hélène M. Faessel, Huamao Lin, Yanyan Zhu, Fred Saad, David B. MacLean, Neal D. Shore
Source: European Urology - Category: Urology & Nephrology Source Type: research
Publication date: Available online 6 April 2020Source: European UrologyAuthor(s): Sigrid V. Carlsson, James A. Eastham, E. David Crawford, Richard G. Harris
Source: European Urology - Category: Urology & Nephrology Source Type: research
We present recent series examining sequencing of approved therapies while searching for predictive biomarkers. Finally, we examine trials evaluating novel agents that target certain biological pathways to highlight the likely future directions for progress in the clinical management of advanced prostate cancer.
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research
Purpose of review The present article highlights the most common DNA repair gene mutations, using specific examples of individual genes or gene classes, and reviews the epidemiology and treatment implications for each one [with particular emphasis on poly-ADP-ribose polymerase (PARP) inhibition and PD-1 blockade]. Recent findings Genetic and genomic testing have an increasingly important role in the oncology clinic. For patients with prostate cancer, germline genetic testing is now recommended for all men with high-risk and metastatic disease, and somatic multigene tumor testing is recommended for men with metastatic ...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research
Purpose of review The present review describes the current role of metabolic imaging techniques such as multiparametric MRI (mpMRI), magnetic resonance spectroscopic imaging (MRSI), hyperpolarized MRSI, and positron emission tomography (PET) in the diagnosis of primary prostate cancer, surveillance of low-grade disease, detection of metastases, and evaluation of biochemical recurrence after therapy. Recent findings The natural history of prostate cancer ranges from indolent disease that is optimally monitored by active surveillance, to highly aggressive disease that can be lethal. Current diagnostic methods remain imp...
Source: Current Opinion in Oncology - Category: Cancer & Oncology Tags: GENITOURINARY SYSTEM: Edited by Arif Hussain Source Type: research
TUESDAY, April 7, 2020 -- In a special article published online April 1 in Advances in Radiation Oncology, a framework is laid out for the management of radiotherapy for prostate cancer patients during the coronavirus disease 2019 (COVID-19)...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Condition:   Prostate Cancer Intervention:   Drug: MBM-02 (Tempol) Sponsor:   Matrix Biomed, Inc. Available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Biochemically Recurrent Prostate Carcinoma;   Prostate Adenocarcinoma Interventions:   Biological: Durvalumab;   Drug: Olaparib;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsors:   University of Washington;   National Cancer Institute (NCI);   AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Prostate Cancer;   Refractory Cancer;   Castration Resistant Prostatic Cancer Intervention:   Drug: Omeprazole 80 mg twice daily Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Prostate Cancer | Radiology